SCHEMBL3975862

SCHEMBL3975862

NC(=O)c1ccc(CC(=O)NS(=O)(=O)Cc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.53
PLA2G2A P14555 1/20 0.53
RORC P51449 1/20 0.47
P4HTM Q9NXG6 1/20 0.47
PARP10 Q53GL7 1/20 0.47
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
EGFR P00533 4/20 0.46
ERBB2 P04626 4/20 0.46
HPGD P15428 1/20 0.46
CA5A P35218 3/20 0.45
CA7 P43166 3/20 0.45
CA5B Q9Y2D0 3/20 0.45
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975864 0.85 CNR2 (0.52) P4HTMCA1CA2MMP1MMP2
SCHEMBL3975403 0.81 EGFR (0.69) PLA2G10PLA2G2AP4HTMEGFRERBB2
SCHEMBL3978336 0.78 EGFR (0.40) PLA2G10PLA2G2APARP10CA2EGFR
SCHEMBL3936655 0.78 CA1 (0.58) P4HTMCA1CA2MMP1MMP2
SCHEMBL3936649 0.77 CA1 (0.56) P4HTMCA1CA2MMP1MMP2
SCHEMBL732335 0.76 CA1 (0.60) P4HTMCA1CA2MMP1MMP2
Fluoride SCHEMBL5153720 0.75 CA1 (0.58) P4HTMCA1CA2MMP1MMP2
SCHEMBL9911079 0.74 ACLY (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL3977341 0.74 CA1 (0.48) PLA2G10PLA2G2ACA1CA2MMP1
SCHEMBL3973361 0.74 EGFR (0.52) PLA2G10PLA2G2AEGFRERBB2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569602-B2 Furan derivatives as EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-08-04 US disclosed
EP-1673360-B1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-12-17 EP disclosed
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2008-12-11 US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 US disclosed
EP-1673360-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2006-06-28 EP disclosed
US-20050124676-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2005-06-09 US disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124676-A1 EP4 receptor antagonists PTGER4, PTGER3, NR4A3 PLA2G10 1590/4885PLA2G2A 1796/4885RORC 1358/4885
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER3, NR4A3 PLA2G10 1590/4885PLA2G2A 1796/4885RORC 1358/4885
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists PTGER4, PTGER3, NR4A3 PLA2G10 1762/4885PLA2G2A 1789/4885RORC 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.